中国实用外科杂志2024，Vol.44Issue(1)：98-102,5.DOI:10.19538/j.cjps.issn1005-2208.2024.01.16
中国118家三级医院早期HER2阳性乳腺癌新辅助治疗现状调查报告
A questionnaire-based investigation on the status of neoadjuvant therapy for early-stage HER2-positive breast cancer in 118 tertiary hospitals in China
摘要
Abstract
Objective To investigate the status of neoadjuvant therapy for early HER2-positive breast cancer in China.Methods A questionnaire-based survey was conducted to investigate the treatment of patients with breast cancer from January 1,2023 to June 30,2023.The investigation content included the qualification of pathological department,certification of HER2 test reagent,the number of early breast cancer cases,the number of HER2-positive breast cancer cases,the number of cases receiving neoadjuvant therapy with anti-HER2 therapy and the pathological result after neoadjuvant therapy.Results A total of 118 tertiary hospitals from 13 provinces participated in the investigation,including 99 general hospitals and 19 oncology hospitals.Among them,85 hospitals(72％)had both pathological department qualification and certificated HER2 test reagent approved by the National Medical Products Administration,and 33 hospitals(28％)failed to provide pathological department qualification or reagent certification.A total of 39014 cases of patients with early-stage breast cancer were admitted in 118 hospitals.9160(23.5％)cases were HER2-positive breast cancer.3222(35.2％)patients received neoadjuvant therapy with dual HER2-targeted regimen,with pCR rate of 51.3％.The pCR rate after neoadjuvant therapy with dual HER2-targeted regimen in hospitals with qualification was significantly higher than that those hospitals without certification(56.2％vs 48.0％,P=0.046).Conclusion To improve the qualification of pathological department and HER2 test certification is an important measure to achieve clinical homogenization of diagnosis and treatment for breast cancer.关键词
乳腺癌/HER2阳性/新辅助治疗/病理质控Key words
breast cancer/HER2 positive/neoadjuvant therapy/pathological quality control分类
医药卫生引用本文复制引用
辛灵,周思成,江泽飞,刘荫华,中国临床肿瘤学会乳腺癌专业委员会,中华医学会外科学分会乳腺外科学组..中国118家三级医院早期HER2阳性乳腺癌新辅助治疗现状调查报告[J].中国实用外科杂志,2024,44(1):98-102,5.基金项目
中国乳腺外科青年医生基金项目(No.2020-CHPASLP-01,No.CJBSRAF-2022) （No.2020-CHPASLP-01,No.CJBSRAF-2022）
北京医学奖励基金会项目(No.YXJL-2020-0941-0736) （No.YXJL-2020-0941-0736）
